BUFFALO, NY / ACCESSWIRE / July 14, 2023 / Buffalo, NY-based biopharmaceutical startup POP Biotechnologies (POP BIO) is conducting Phase 3 of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). The company announced the topline interim results of the clinical trial. . EuCorVac-19 is a protein-based vaccine composed of vaccine antigens displayed on immunogenic nanoparticles using POP BIO’s spontaneous nanoliposomal antigenic particle (SNAP) technology.
EuCorVac-19, a recombinant protein vaccine displaying the SARS-CoV-2 receptor binding domain (RBD) antigen on immunogenic liposomes
A Phase 3 trial of EuCorVac-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-19 met the primary endpoint of the Phase 3 trial, demonstrating superior antibody immunogenicity compared to adenoviral vector vaccines licensed for emergency use by the World Health Organization.
The formation of neutralizing antibodies that protect against COVID-19 was more than doubled with EuCorVac-19 compared to the control vaccine. EuCorVac-19 showed high serological response rates and elevated neutralizing antibody titers after vaccination. Notably, neutralizing antibody titers and seroreactivity rates in subjects aged 65 years and older exceeded those of the control vaccine. In an immunogenicity assay against the Omicron BA.5 strain, EuCorVac-19 induced more than 2-fold neutralizing antibody titers compared to the control vaccine.
The safety profile of EuCorVac-19 was further established in this Phase 3 trial. EuCorVac-19 had a slightly lower rate of solicited adverse events than the control vaccine, and there was no difference in the rate of unsolicited adverse events between EuCorVac-19 and the control vaccine.
These results further validate the strength and synergy of POP BIO’s SNAP and EuBiologics’ EuIMT platform technologies used in the EuCorVac-19 vaccine. In the future, further development of COVID-19 booster, novel strain and combination vaccines will be greatly facilitated.
“Achieving completion of this Phase 3 trial is a major milestone for our technology. These results not only provide validation towards a solution to this unprecedented global crisis, but also support the development of our platform. will provide valuable support to POP BIO and further enable the development of new vaccines with tremendous potential to “alleviate suffering around the world,” said Jonathan Smith, co-founder of POP BIO.
EuCorVac-19 has already been shown to be safe and immunogenic in Phase I/II clinical trials, the results of which were announced in December 2021. The Phase 3 trial in the Philippines, which began in the third quarter of 2022, is a Korea Health Technology R&D Project by the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare of Korea.
Based on the results of this clinical study, EuBiologics will soon apply for product approval in the Philippines. Results from his second independent Phase 3 clinical trial, being conducted in the Democratic Republic of the Congo, are expected later this year.
About POP Biotechnologies: POP Biotechnologies, Inc. is a privately held biotechnology company focused on the research and development of novel therapeutics and vaccines based on proprietary porphyrin phospholipid (PoP) liposome technology. The PoP technology is exclusively licensed from the State University of New York Research Foundation (SUNY-RF) and developed at the State University of New York at Buffalo (SUNY Buffalo) academic facility by the company’s co-founder, Dr. Jonathan Lovell. it was done. POP Biotechnologies now resides in his SUNY Buffalo Incubator at Baird Research Park.
About POP BIO’s SNAP technology: POP BIO’s Spontaneous Nanoliposome Antigen Particulation (SNAP) technology is a highly immunogenic particle-based vaccine and immunotherapy for infectious diseases and cancers using a cobalt-modified variant (CoPoP) of the PoP technology. Enables rapid development and manufacturing. SNAP technology enables the seamless generation of stable particle formation and liposome display of protein and peptide antigens, significantly improving immune responses.
About EuBiologics: EuBiologics is a South Korean biotechnology company developing the EuCorVac-19 COVID-19 vaccine and other vaccine products. EuBiologics has two major animal-based biologics for producing recombinant protein antigens at Chuncheon Factory 1 (C Factory) and adjuvant EcML (Monophosphoryl Lipid A) at Chuncheon Factory 2 (V Factory). Equipped with a reactor (1,000 L). Total production capacity for COVID-19 vaccines is now in the hundreds of millions of doses per year.
About EuBiologics’ EuIMT technology: EuBioloigcs’ immunomodulatory technology uses a proprietary TLR4 agonist, a genetically engineered monophosphoryl lipid A (MLA) called EcML. EuBiologics has intellectual property protection for EcML and various adjuvant systems, including EcML. Eubiologics’ EcML and POP BIO’s SNAP technology synergize to create a super-potent next-generation vaccine.
sauce: POP Biotechnologies
View the source version on accesswire.com.